Curium's Lantheus deal is worth up to $114.50 a share. Only $102.50 of it is a price.

On 3 August, Curium agreed to acquire Lantheus for $102.50 per share in cash, plus non-transferable contingent value rights worth up to $12.00 more — a transaction the companies size at up to roughly $8.0 billion, closing expected in the first half of 2027.

Three days later, Lantheus reported second-quarter results, suspended its full-year 2026 guidance and skipped its earnings call. Normal housekeeping for a company under agreement. It also happens to be the last clean look at the business whose sales decide whether that extra $12.00 ever arrives.

Read the two together and you get the most useful skill in deal coverage: telling a price from a bet.

What a contingent value right actually is

A CVR is a contractual promise from the buyer to pay more later if specified things happen. It is not stock. It is not escrow. It is an unsecured IOU whose value depends on a business you no longer own, run by people you did not hire.

This one is non-transferable, which is the detail most retail coverage skips. You cannot sell it. There is no ticker, no bid, no quote to check your position against. You take the $102.50 at closing, and then you hold a piece of paper until 2030 tells you whether it was worth anything.

The eight milestones, and where the money sits

The announcement lists each tranche:

Franchise	Sales threshold	Payment per share
Prostate cancer diagnostics (through 2030)	$950M	$1.00
Prostate cancer diagnostics	$1,100M	$1.00
Prostate cancer diagnostics	$1,200M	$2.00
Prostate cancer diagnostics	$1,500M	$2.00
Prostate cancer diagnostics	$1,750M	$2.00
Neurology diagnostics (FY2028–2030)	$300M	$2.00
Neurology diagnostics	$350M	$1.00
DEFINITY (2030)	$400M	$1.00

Note the concentration. Two thirds of the contingent value rides on a single franchise, prostate cancer diagnostics, and the largest tranches sit at the highest thresholds. That is a normal way to structure a CVR — the buyer pays most for the outcome it is least willing to underwrite up front.

Is $950 million a stretch?

Lantheus published the yardstick itself on 6 August. PYLARIFY, its PSMA imaging agent and the bulk of the prostate diagnostics franchise, did $240.4 million in the quarter, down 4.1% year over year. Four quarters at that rate is roughly $960 million.

So the cheapest tranche in the table asks a franchise that is currently shrinking to hold approximately its present run rate. The top tranche asks it to grow toward twice that. Between them sit three more steps, each requiring the decline to reverse and then keep going.

The other two franchises land differently. DEFINITY did $88.3 million in the quarter and grew 5.2% — an annualised rate already inside sight of its $400 million threshold, and worth $1.00. Neuraceq did $39.6 million against a neurology threshold of $300 million in fiscal 2028, and that one pays $2.00.

Read the pattern: the milestone most likely to hit is worth the least, and the milestones worth the most need the hardest growth from the weakest starting point. That is the design working as intended, and it is why "up to $114.50" and "$102.50" are not close to the same statement.

What the 38% premium is measured against

The release quotes a premium of 38% to Lantheus's unaffected 60-day volume-weighted average price and 29% to the 30-day, both as of 21 May 2026. Volume-weighted average price is just the average trade price over a window, weighted by how much stock changed hands at each level.

"Unaffected" is the load-bearing word. It means the price before deal reports moved the stock. Measuring against it is a defensible convention — a buyer should not get credit for a premium over a price its own leaked negotiations created. It also means the 38% is not the premium to where shares traded the day before the announcement. Both facts are true at once, and only one of them describes what a holder who bought last month is being handed.

What the announcement does not tell you

Naming the gaps is more useful than filling them:

• Whether the thresholds are annual or cumulative. The release gives a number and a period for each tranche. The operative definitions live in the merger agreement, not the press release.
• What counts inside each franchise. "Global prostate cancer diagnostics" is a category, not a product line. PYLARIFY dominates it, but the release does not publish the boundary — so the run-rate arithmetic above is an approximation, not the covenant.
• What efforts the buyer owes. After closing, Curium controls pricing, promotion and investment in the very products whose sales determine the payout. Every CVR carries that structural conflict; the disclosed summary does not say what commercially-reasonable-efforts covenant, if any, constrains it.
• Antitrust. Two radiopharmaceutical competitors are combining, and the timeline implies close to a year of review. The financing carries no conditions, but regulatory clearance is a different question entirely.

What to watch

• The proxy statement and merger agreement, which will define the sales categories and the efforts covenant. That document, not the press release, is where the CVR's real value is set.
• PYLARIFY's trajectory over the next two quarters, and whether the newly approved TruVu formulation, due commercially in the fourth quarter, stabilises it. The first tranche turns on that line.
• Antitrust review, and whether any divestiture is required — divesting into the prostate franchise would cut directly into the CVR thresholds.
• Any appraisal or shareholder litigation over the split between certain cash and contingent value.

The portable lesson is a habit, not a view on this deal. When a headline says "up to," find the floor first and treat everything above it as a separate, unpriced instrument you are being asked to accept in place of money. Sometimes that instrument pays. When it does not, the answer to "what did the deal pay?" was always the first number.

This is analysis, not investment advice. It describes what has been disclosed and what has not, and does not recommend any position in any security.